Viva biotech announced 2021 annual results: revenue increased by 201.9% yoy, cro business revenue maintained rapid growth with an increase of 68.7%

Financial highlights of the year ended december 31, 2021: revenue amounted to rmb2,104.1 million, representing a year-on-year (yoy) increase of 201.9% gross profit amounted to rmb651.0 million, representing a yoy increase of 113.5% adjusted non-ifrs net profit amounted to rmb352.5 million adjusted earnings per share amounted to hk$0.21 hongkong, march 28, 2022 /prnewswire/ -- on march 28, 2022, viva biotech holdings (1873.hk) announced that during the year ended december 31, 2021 (the "reporting period"), the revenue of the group increased significantly to rmb2,104.1 million from rmb697.0 million for the corresponding period last year, representing a yoy increase of approximately 201.9%, gross profit increased substantially from rmb304.9 million for the corresponding period last year to rmb651.0 million, representing a yoy increase of 113.5%. the adjusted net profit of the group increased from rmb252.3 million for the corresponding period last year to rmb352.5 million, representing a yoy increase of 39.7%.
ABSI Ratings Summary
ABSI Quant Ranking